



GlaxoSmithKline
Patrick M. McLain
Vice President
Federal Government Relations
1050 K Street, NW
Suite 800
Washington, DC
20001

Tel. 202 715 1039
Fax 202 715 1001
Patrick.M.McLain@gsk.com
www.gsk.com

December 10, 2008

The Honorable Charles E. Grassley
Ranking Member
Committee on Finance
United States Senate
Washington, D.C. 20510-6200

**GLAXOSMITHKLINE CONFIDENTIAL.
NOT FOR PUBLIC RELEASE OR
DISSEMINATION. PROVIDED TO THE
COMMITTEE ON FINANCE PURSUANT TO
REQUEST DATED MAY 6, 2008. ALL RIGHTS
RESERVED.**

Re: ***Correspondence to Christopher Viehbacher
Dated May 6, 2008***

Dear Senator Grassley:

This letter is submitted on behalf of GlaxoSmithKline (“GSK”) in response to a request I received on December 8, 2008 from your staff. Specifically, your staff had a question regarding a prior submission from GSK which was submitted in response to your May 6, 2008 letter to Christopher Viehbacher requesting information regarding payments from GSK to certain doctors specified in the May 6, 2008 letter and by subsequent communication with GSK’s counsel. GSK made an initial response to this letter on May 27, 2008 and a supplemental response on July 18, 2008.


On December 8, 2008, your staff requested that I put certain information into a letter. Your staff referenced an earlier e-mail exchange, which I assume refers to a September 5, 2008 e-mail from me to Paul Thacker in response to his e-mail from September 4, 2008, which raised a question regarding speakers bureau payments. Per your staff’s request that certain information be placed in writing, please be advised of the following:

- (1) GSK’s July 18, 2008 submission consisted of information obtained by searching its speaker event and professional programs databases for payment information, including both honoraria and expense reimbursement, for the time period from January 1, 2000 through April 30, 2008;

- (2) The July 18, 2008 submission contained payment information for product talks for the specified physicians;
- (3) The July 18, 2008 submission also contained information regarding additional payments for other activities, such as National Advisory Boards. To the extent there were additional activities other than product talks, those would be identified under the XTYPE column in Exhibit A, which was produced as part of the July 18, 2008 submission.

We hope this information is helpful to your inquiry. If you have any additional questions regarding this matter, or need further information, please do not hesitate to call me at (202) 715-1039.

Sincerely,

A handwritten signature in black ink, appearing to read "Patrick M. McLain". The signature is written in a cursive style with a large initial "P" and a long, sweeping underline.

Patrick M. McLain

cc: The Honorable Max Baucus, Chairman